TY - JOUR
T1 - Platelet-activating factor receptor gene polymorphism in Japanese patients with multiple sclerosis
AU - Osoegawa, Manabu
AU - Miyagishi, Ryuji
AU - Ochi, Hirofumi
AU - Nakamura, Itta
AU - Niino, Masaaki
AU - Kikuchi, Seiji
AU - Murai, Hiroyuki
AU - Fukazawa, Toshiyuki
AU - Minohara, Motozumi
AU - Tashiro, Kunio
AU - Kira, Jun Ichi
N1 - Funding Information:
We thank Ms. N. Kinukawa (Department of Medical Information Science, Kyushu University Hospital) for help with statistical analyses. This work was supported, in part, by grants from the Ministry of Education, Science, Sports, and Culture of Japan, the Neuroimmunological Disease Research Committee, and the Ministry of Health and Welfare of Japan for Research on Brain Science.
PY - 2005/4
Y1 - 2005/4
N2 - We evaluated the association of the platelet-activating factor receptor (PAFR) gene polymorphism (A224D) with the susceptibility and severity of multiple sclerosis (MS) in a Japanese population. DNA was collected from 162 Japanese patients with clinically definite 'conventional' MS (MS) and 245 healthy controls. The missense mutation A224D that impairs PAF-PAFR signaling was determined by polymerase chain reaction restriction fragment length polymorphism. The frequency of the AD/DD genotypes was significantly higher in MS patients (21.0%) than in healthy controls (13.5%) (p=0.045; odds ratio (OR), 1.71; 95% confidence interval (CI), 1.01-2.89). Moreover, the frequency of D allele in MS patients (11.7%) was also significantly higher than those in healthy controls (6.9%) (p=0.019; OR, 1.78; 95% CI, 1.10-2.89). These findings suggest that the PAFR gene missense mutation has a relation to the susceptibility for MS.
AB - We evaluated the association of the platelet-activating factor receptor (PAFR) gene polymorphism (A224D) with the susceptibility and severity of multiple sclerosis (MS) in a Japanese population. DNA was collected from 162 Japanese patients with clinically definite 'conventional' MS (MS) and 245 healthy controls. The missense mutation A224D that impairs PAF-PAFR signaling was determined by polymerase chain reaction restriction fragment length polymorphism. The frequency of the AD/DD genotypes was significantly higher in MS patients (21.0%) than in healthy controls (13.5%) (p=0.045; odds ratio (OR), 1.71; 95% confidence interval (CI), 1.01-2.89). Moreover, the frequency of D allele in MS patients (11.7%) was also significantly higher than those in healthy controls (6.9%) (p=0.019; OR, 1.78; 95% CI, 1.10-2.89). These findings suggest that the PAFR gene missense mutation has a relation to the susceptibility for MS.
UR - http://www.scopus.com/inward/record.url?scp=20044388138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20044388138&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2004.12.014
DO - 10.1016/j.jneuroim.2004.12.014
M3 - Article
C2 - 15748960
AN - SCOPUS:20044388138
SN - 0165-5728
VL - 161
SP - 195
EP - 198
JO - Advances in Neuroimmunology
JF - Advances in Neuroimmunology
IS - 1-2
ER -